Lung adenocarcinoma remains a notoriously aggressive and deadly form of cancer, representing over 50% of all lung cancer diagnoses worldwide. Its insidious nature, marked by late-stage detection and a high propensity for recurrence, has historically limited therapeutic success. Standard chemotherapy regimens, though somewhat effective, tend to indiscriminately assault both malignant and healthy cells alike, resulting in debilitating side effects including hair loss, nausea, immunosuppression, and compromised patient quality of life. Furthermore, the inefficiencies in targeted drug delivery often diminish the potency of these treatments, underscoring the urgent need for more sophisticated therapeutic modalities.

In addressing these critical challenges, the KRIBB team has innovated the A5 nanobody, a miniature and highly specific antibody fragment engineered to bind selectively to CD155, a protein ubiquitously overexpressed on lung cancer cells but scarcely present on normal tissues. Unlike conventional antibodies, which are considerably larger, the A5 nanobody is approximately ten times smaller, endowing it with superior tissue penetration capabilities. This compact structure not only enhances its ability to navigate the complex microenvironment of tumors but also optimizes binding affinity, ensuring that the therapeutic agent homes in exclusively on malignant cells.

Integral to the therapeutic function of the A5 nanobody is its capacity to inhibit critical processes in cancer progression. Laboratory investigations have demonstrated that the A5 nanobody effectively suppresses lung cancer cell migration and invasion by over 50%, mechanisms central to metastasis formation and disease advancement. This functional blockade serves as a potent therapeutic intervention point, potentially stalling tumor spread at an early stage and improving clinical outcomes.

Expanding upon this targeting mechanism, the researchers engineered an advanced drug delivery system dubbed A5-LNP-DOX, wherein the A5 nanobody is conjugated to liposomal nanoparticles encapsulating doxorubicin (DOX), a widely used and potent chemotherapeutic agent. The use of liposomes serves a dual purpose: it protects the encapsulated drug from premature degradation and enables controlled release within the tumor microenvironment. The conjugation with the A5 nanobody ensures that these liposomes specifically dock onto CD155-expressing cancer cells, facilitating a “guided missile” or “drone strike” approach to chemotherapy administration.

Empirical data from in vitro studies revealed that this precision delivery system vastly outperforms conventional methods, achieving up to a threefold increase in doxorubicin uptake within lung cancer cells. This enhanced internalization significantly amplifies cytotoxic effects on malignant cells while sparing healthy tissues, thereby alleviating the systemic toxicity traditionally associated with doxorubicin therapy. The targeted modality of A5-LNP-DOX represents a transformative leap towards maximizing therapeutic indices in oncology.

The therapeutic promise of A5-LNP-DOX extends beyond cell cultures; it has been rigorously evaluated in vivo across animal models and patient-derived organoids, systems that faithfully recapitulate human tumor biology. Results demonstrated a remarkable 70 to 90 percent reduction in tumor burden, coupled with elevated markers of cancer cell apoptosis and necrosis. Importantly, these outcomes were achieved without detectable adverse effects on critical vital organs such as the liver, heart, and kidneys, reinforcing the safety profile of this nanobody-guided chemotherapeutic strategy.

Central to this breakthrough is the selective targeting of CD155, also known as the poliovirus receptor, whose overexpression in lung adenocarcinoma offers an exploitable vulnerability. Its role in tumor immune evasion and cellular adhesion makes CD155 an attractive target for therapeutic interference. The innovative binding specificity of the A5 nanobody towards this target enables precise intervention within oncogenic signaling pathways while minimizing off-target interactions that have plagued earlier treatments.

Beyond its immediate application to lung adenocarcinoma, this nanobody-based platform is poised for broad-spectrum adaptability. Dr. Juyeon Jung emphasizes the versatility inherent in the technology, envisioning its adaptation to other cancer types characterized by distinct surface markers, thus inaugurating a new era of precision medicine. The capacity to engineer nanobodies against a multitude of tumor-associated antigens holds promise for tailored therapies that maximize efficacy and patient tolerability.

The development process also reflects an elegant integration of biotechnology and nanomedicine, domains rapidly converging to revolutionize modern therapeutics. The liposomal drug carriers combined with compact, high-affinity nanobodies exemplify how biomolecular engineering can enhance pharmacodynamics and pharmacokinetics concurrently. These advances collectively pave the way for therapeutic regimens that can be finely tuned to individual patient tumor profiles, elevating personalized medicine from concept to clinical reality.

Funding and support from the Ministry of Science and ICT (MSIT), the Korea Agency of Education, Promotion and Evaluation for Food, Agriculture, Forestry and Fisheries (IPET), and the KRIBB Research Initiative Program have been instrumental in driving this research. The collaborative nature of this endeavor underscores the significance of sustained investment in cutting-edge basic and translational science, which continues to yield innovations capable of dramatically improving cancer care trajectories.

Published in the highly acclaimed journal Signal Transduction and Targeted Therapy on July 10, 2025, this landmark study entitled “Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery” sets a new benchmark in oncology drug design. The high impact factor of the journal attests to the global relevance and timely nature of this work, signaling robust peer validation within the scientific community.

In summary, the advent of the A5 nanobody and its integration into targeted liposomal chemotherapeutics represents a transformative strategy in lung adenocarcinoma treatment. By offering a mechanism to not only selectively identify but also effectively neutralize cancer cells with minimal collateral damage, this technology exemplifies the future of oncology – one characterized by precision, efficacy, and patient-centered care. Continuing clinical development and eventual translation into therapeutic applications could profoundly alter the prognosis for patients suffering from lung cancer worldwide.

Subject of Research: Nanobody-based targeted therapy and drug delivery for lung adenocarcinoma focusing on CD155 protein.

Article Title: Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery

News Publication Date: 10-Jul-2025

Web References: http://dx.doi.org/10.1038/s41392-025-02301-z

Image Credits: Korea Research Institute of Bioscience and Biotechnology (KRIBB)

Keywords: Lung adenocarcinoma, nanobody, CD155, targeted therapy, doxorubicin, liposomal nanoparticles, precision medicine, KRIBB, drug delivery, cancer metastasis, antibody engineering, non-small cell lung cancer

One of the highlighted projects is spearheaded by Distinguished Professor Andrew Mesecar, a leader in cancer structural biology and director of the Purdue Institute for Cancer Research. His work focuses on developing potent inhibitors targeting Ubiquitin Specific Protease 7 (USP7), a human enzyme implicated in hepatocellular carcinoma (HCC), the most prevalent form of liver cancer worldwide. Mesecar’s approach is notable for its selectivity: the compounds under development inhibit USP7 through a unique binding mechanism distinct from the enzyme’s catalytic site, which sets them apart from existing inhibitors and promises reduced off-target effects, a critical hurdle in drug development.

The significance of Mesecar’s research lies not only in its molecular specificity but also in the broader public health context. HCC presents formidable challenges, with rising incidence rates and a dearth of effective therapies leading to high mortality worldwide. By advancing novel, patent-backed compounds that selectively shut down USP7 activity, Mesecar and his team aim to pioneer a new class of therapeutics that could improve clinical outcomes and reduce treatment-related economic burdens. The Trask Innovation Fund award will support the synthesis of refined molecules with enhanced drug-like properties and higher efficacy across diverse HCC cell lines, paving the way toward preclinical validation.

In parallel, the College of Engineering’s Jerry M. and Lynda T. Engelhardt Professor Pablo Zavattieri is leading an innovative project to develop a reconfigurable and navigable waterway barrier (RNWB) designed to tackle saltwater intrusion in the Panama Canal. This effort responds to critical environmental and economic pressures fueled by climate change, increased water use resulting from Neopanamax vessels, and dwindling freshwater reserves in Gatun Lake, which is essential for the canal’s operation. Saltwater contamination threatens both potable water supplies and the canal’s operational efficiency, posing risks to global maritime trade.

Zavattieri’s RNWB leverages advanced materials engineered at Purdue to prevent the mixing of saltwater and freshwater during ship transits through the canal. The design is patent-pending and represents a sophisticated solution that balances ecological preservation with economic imperatives. By effectively isolating saltwater, the barrier could sustain freshwater availability, maintain canal throughput, and mitigate revenue losses tied to reduced transit capacity. This technology has garnered strong interest from the Panama Canal Authority (ACP), with which Purdue maintains a collaborative relationship bolstered by connections such as former ACP Vice President and Purdue alumnus Luis Alfaro.

Central to the RNWB project is the plan to use the Trask funding for a six-month intensive phase that will refine barrier design, fabricate a proof-of-concept prototype, and conduct controlled testing within Purdue’s facilities. These steps are critical to de-risk the technology, demonstrate feasibility, and lay the foundation for commercial partnerships. Discussions with ACP have already explored viable business models, including startup formation and licensing pathways, highlighting the translational impact of the research. Successful deployment of the RNWB could revolutionize how critical waterways address saltwater intrusion globally, extending Purdue’s legacy of practical civil engineering solutions.

The Trask Innovation Fund itself plays an instrumental role in bridging what innovators call the “valley of death” — the often-prolonged gap between academic invention and marketable product. Managed by Purdue Innovates Incubator, the fund provides crucial resources allowing researchers to generate data, build prototypes, validate concepts, and advance commercialization strategies. Its support complements a broader ecosystem fostering entrepreneurial activities, including customer discovery, regulatory guidance, team building, and business modeling. As fund manager Matt Dressler explains, this financial and programmatic support accelerates the translation of early-stage discoveries, making them attractive to industry partners and investors.

Purdue Innovates Incubator serves as the gateway to these innovation resources, offering Purdue-affiliated inventors and entrepreneurs valuable programming and mentorship opportunities. By aligning technical research with strategic business acumen, the incubator enhances the likelihood that transformative ideas reach the marketplace and create tangible societal benefits. The incubator team actively encourages alumni and community members to contribute as mentors, creating a dynamic network that bridges academia and industry.

Purdue University’s stature as a leading public research institution bolsters the visibility and impact of projects like those funded by the Trask Innovation Fund. Ranked among the top 10 public universities nationwide, Purdue harnesses a vast and diverse community of over 107,000 students and multiple campuses to foster interdisciplinary research excellence. Its sustained commitment to affordability, exemplified by a 14-year tuition freeze at its main campus, reflects a broader vision to democratize access to knowledge and innovation.

The innovative scope of the USP7 inhibitors offers promising advancements in biomedical science, specifically targeting the mechanistic underpinnings of cancer proliferation. By focusing on an allosteric site distinct from active centers commonly targeted by drugs, Mesecar’s compounds exploit novel inhibitory pathways, potentially minimizing adverse interactions seen in existing treatments. Such precision medicine approaches are critical in addressing complex diseases like HCC, where heterogeneity and drug resistance complicate therapy.

On the environmental engineering front, Zavattieri’s RNWB represents a significant leap in infrastructure design, combining material science and civil engineering principles with real-world environmental challenges. The dynamic and reconfigurable nature of the barrier allows it to adapt to the canal’s operational requirements and variable hydrological conditions. By enabling navigable passage for Neopanamax vessels without compromising freshwater stores, the RNWB could substantially enhance the canal’s resilience to climate-induced stresses and escalating maritime demands.

These projects epitomize the convergence of scientific inquiry and practical application, demonstrating how university research can address global challenges in health and environmental management. The strategic use of intellectual property protection ensures that these innovations retain commercial viability while preserving the incentives for continued academic exploration and collaboration.

Furthermore, the emphasis on commercialization pathways illustrates a holistic approach to research translation, where technical development is integrated with market analysis, stakeholder engagement, and scalable business models. This synergy amplifies the potential impact of Purdue’s innovations, positioning them for success not only in the lab but also in real-world deployment.

As the academic year progresses, the outcomes of these projects will likely inform broader discussions on the role of university-driven innovation funds and incubators in accelerating the pace at which cutting-edge discoveries improve human health and environmental sustainability. By fostering collaboration across disciplines and engaging with global partners such as the Panama Canal Authority, Purdue sets a compelling model for impactful, solution-oriented research.

In summary, the Trask Innovation Fund’s support of Andrew Mesecar’s novel USP7 inhibitors and Pablo Zavattieri’s reconfigurable waterway barrier exemplifies the power of targeted investment in early-stage technologies. Both endeavors harness Purdue’s rich expertise and resources to confront pressing issues—cancer therapeutics and freshwater conservation—with transformative potential. As these projects advance toward commercialization, they underscore the vital role that academic innovation ecosystems play in shaping the future of science, technology, and global well-being.

Subject of Research:
Cancer therapeutics targeting USP7 enzyme for hepatocellular carcinoma treatment; Reconfigurable waterway barrier technology addressing saltwater intrusion in critical maritime infrastructure.

Article Title:
Purdue Innovates with Novel Cancer Therapeutics and Waterway Barrier Technologies Backed by Trask Innovation Fund

News Publication Date:
Spring 2025

Web References:

• Purdue Innovates Trask Innovation Fund: https://purdueinnovates.org/incubator/trask-innovation-fund/
• Purdue Institute for Cancer Research: https://www.purdue.edu/cancer-research/
• Lyles School of Civil and Construction Engineering: https://engineering.purdue.edu/CCE
• Purdue Innovates Incubator: https://purdueinnovates.org/incubator/

Image Credits:
Purdue University photo/Nelson Pachao Morbitzer

Keywords:
Research funding, Cancer, Liver cancer, Cancer medication, Cancer treatments, Water management, Freshwater resources, Man made structures, Civil engineering, Transportation infrastructure

Thyroid cancers such as anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC) are characterized by their aggressive nature and poor prognosis, with conventional treatments offering limited survival benefits and an average patient lifespan often measured in months. AIC100’s targeted mechanism seeks to address the critical unmet need in these diseases by leveraging the immune system’s cytotoxic T lymphocytes, reprogrammed to recognize and eradicate ICAM-1 expressing tumor cells. This therapeutic approach not only signifies a novel strategy for thyroid cancers but also expands the potential horizons of CAR T cell technology.

The AIC100 construct represents a third-generation CAR T cell, incorporating enhancements intended to improve efficacy and persistence within the hostile tumor microenvironment of solid cancers. Specifically, AIC100’s CAR molecule binds the ICAM-1 protein, a transmembrane glycoprotein frequently overexpressed in ATC and PDTC cells, facilitating tumor infiltration and cytotoxic activity. Importantly, the CAR T cells co-express somatostatin receptor 2, allowing real-time in vivo tracking using positron emission tomography (PET) imaging, a sophisticated adaptation that enables clinicians to monitor distribution and treatment response non-invasively.

In this multicenter Phase I trial, 24 adult patients with newly diagnosed or relapsed/refractory ATC or PDTC were enrolled, many of whom had exhausted standard-of-care therapies with an average of two prior treatment regimens. The study employed a dose-escalation design exploring three initial dose levels of AIC100 administered after a lymphodepleting chemotherapy regimen, intended to enhance CAR T cell engraftment by reducing host regulatory immune cells. Of these patients, 15 received the investigational therapy, and evaluable data from dose levels two and three revealed encouraging clinical activity.

Specifically, among four ATC patients treated at the higher dose cohorts, the overall objective response rate reached 50%, with one achieving a complete response and another demonstrating a partial response. This level of tumor reduction and durable disease control, sustained up to seven months post-infusion, is unprecedented in this patient population. Moreover, in five PDTC patients, 60% experienced disease stabilization, suggesting both types of thyroid cancer may be amenable to this immunotherapeutic approach.

Safety signals from the trial were favorable, with no dose-limiting toxicities observed at the first three dose levels. Most adverse events comprised mild to moderate cytokine release syndrome (CRS), a common immune activation-related toxicity seen in CAR T therapies, which was manageable and transient. Notably, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS), a frequent and serious complication in CAR T cell treatment, were reported. However, exploration of a fourth, escalated dose revealed the emergence of grade 3 pneumonitis in two patients, underscoring the necessity for careful dose optimization.

The safety profile combined with early efficacy led investigators to select dose level three as the recommended dose for future Phase II trials. These findings provide a compelling proof of concept for the application of CAR T cell therapy in solid tumors, an area historically fraught with challenges due to tumor heterogeneity, immune suppression within the tumor microenvironment, and physical barriers to T cell trafficking.

AIC100’s innovative design, including the somatostatin receptor PET-tracking feature, offers an important tool for understanding CAR T cell kinetics and persistence over time, which are critical parameters linked to long-term therapeutic success. This dual functionality may enable dynamic treatment adjustments and early identification of resistance or relapse, ultimately improving patient outcomes through precision immunotherapy.

Samer Srour, MB ChB, associate professor and principal investigator of the trial, emphasized the transformative potential these results hold. He noted that achieving complete and partial remissions in such an aggressive clinical setting is both a validation of the therapeutic strategy and an impetus for further development. The prospect of durable remissions could shift the current therapeutic landscape and significantly extend survival for patients afflicted with these lethal thyroid cancer subtypes.

This Phase I study was funded by AffyImmune Therapeutics, reflecting a productive academic-industry collaboration crucial for advancing cutting-edge immuno-oncology interventions. As the team prepares for larger-scale investigations, the oncology community eagerly anticipates more robust data on efficacy and long-term safety that could pave the way for regulatory approval and expanded clinical use.

In summary, the promising safety and efficacy profile of AIC100 in this early clinical evaluation signals a new frontier in the treatment of solid tumors, highlighting the potential for tailored CAR T cell therapies to overcome previous barriers and improve outcomes in hard-to-treat thyroid cancers. Further developments in this line of research could bring a much-needed paradigm shift, transforming fatal diagnoses into manageable chronic conditions or potentially curable diseases.

Subject of Research: CAR T cell therapy targeting ICAM-1 in aggressive thyroid cancers
Article Title: Novel CAR T Cell Therapy AIC100 Shows Promising Early Results in Aggressive Thyroid Cancers
News Publication Date: April 29, 2025
Web References:

• https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html
• https://www.mdanderson.org/cancer-types/thyroid-cancer.html
• https://faculty.mdanderson.org/profiles/samer_srour.html
• https://www.abstractsonline.com/pp8/#!/20273/presentation/10430
• https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• https://MDAnderson.org/AACR
  Image Credits: The University of Texas MD Anderson Cancer Center
  Keywords: Cancer treatments, Cell therapies, Thyroid cancer, Cancer patients, T cell responses, Clinical trials, T lymphocytes, Thyroid diseases, Gene targeting, Cellular proteins, Solid tumors, Target proteins, Cancer research, Cancer relapse, Neurological disorders, Tumor cells, Disease control

A particularly compelling study delves into the multifaceted role of interleukin-9 (IL-9), a small protein previously known to both exacerbate and inhibit tumor growth, contingent on cancer type. Until now, IL-9’s influence on HNC remained an enigma. The research, led by Sam Nusbaum, reveals that IL-9 expression is notably elevated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) compared to healthy individuals. Intriguingly, higher IL-9 mRNA levels correlated with poor patient survival, underscoring its potential as a prognostic biomarker. At the cellular level, IL-9 appears to induce the secretion of IL-6, a cytokine notorious for impairing the cytolytic function of immune cells tasked with eliminating cancer.

However, the story of IL-9 is far from linear. Experimental animal models demonstrated that increased IL-9 is paradoxically associated with reduced tumor size and weight, hinting at counterbalancing immune responses. This dichotomy suggests that IL-9’s role in tumorigenesis may be context-dependent, influenced by intricate molecular signaling and immune microenvironment dynamics. Nusbaum’s future investigations aim to dissect these pathways in precise molecular detail, shedding light on the dualistic nature of IL-9 in cancer progression and immune regulation.

Complementing this exploration, Lindsey Bachmann investigates signaling pathways integral to the function of natural killer (NK) cells—immune effectors pivotal in identifying and destroying cancer cells. Their research illuminates how blocking the CXCR2 receptor pathway impairs tumor growth in murine models, but only in the presence of NK cells and CD8+ T lymphocytes. CXCR2, a chemokine receptor, is crucial in directing immune cell trafficking and activation within tumors. This finding underscores the therapeutic potential of targeting immune cell receptor signaling to amplify anti-tumor immunity. Ongoing work will elucidate the mechanistic interplay between CXCR2 inhibition and immune effector cell behavior, potentially opening avenues to novel immunotherapies for HNC.

Amid these molecular insights, researchers led by Katelyn Jansen are pioneering efforts to improve noninvasive cancer diagnostics. Traditional tumor biopsies, while the gold standard for evaluating treatment response and disease progression, are often limited by accessibility and patient discomfort. Jansen’s team has standardized protocols for isolating peripheral blood mononuclear cells (PBMCs) from patient blood samples, demonstrating that delayed processing up to 24 hours does not compromise cell viability. This methodological advancement could revolutionize how clinicians monitor immunotherapy responses, allowing for safer, more frequent, and widely accessible assessments. The team plans to validate their findings across multiple institutions and compare PBMC-based analyses with conventional biopsy data to confirm efficacy.

Beyond diagnostics, Jansen also probed the synergistic potential of combining immunotherapy with radiation modalities in recurrent HNC. Specifically, she investigated the effects of proton therapy (PT) versus conventional X-ray radiation therapy (XRT) when paired with immune checkpoint inhibitors like anti-PD1 antibodies. Both PT and XRT effectively stymied tumor growth in vivo and increased immune cell infiltration, yet the addition of immunotherapy conferred only modest additional benefits. These preliminary data suggest that while radiation primes the tumor microenvironment for immune infiltration, the anticipated synergism with immunotherapy remains elusive in animal models. Future experimental designs will aim to optimize these combinatorial strategies, potentially by refining dosing schedules or leveraging novel immune modulators.

Turning to breast cancer, the University of Cincinnati team explored the impact of nonmuscle myosin IIA (NMIIA) within HER2-positive tumors—aggressive breast cancers marked by elevated HER2 protein levels driving rapid proliferation and metastasis. Through molecular interrogation, the team identified NMIIA’s interaction with HER3, a related receptor, modulating intracellular signaling pathways that contribute to drug resistance and metastatic behavior. Clinical correlations revealed that elevated NMIIA expression, particularly in lymphovascular invasion (LVI)-positive tumors, portends worse patient survival. This discovery positions NMIIA as a potential therapeutic target, and the lab is actively developing a novel NMIIA inhibitor. If successful, this approach could augment current HER2-targeted therapies, combating resistance and metastatic spread.

In an altogether different pathological context, lymphangioleiomyomatosis (LAM)—a rare lung disease characterized by cystic lung remodeling due to aberrant smooth muscle-like cell proliferation—has been the focus of cutting-edge metabolic research. First author Evans Abor examined the enzyme PHGDH and its regulatory nexus with mTORC1, a signaling hub known to drive LAM progression. Remarkably, PHGDH expression was markedly increased in diseased tissues. Pharmacological inhibition of PHGDH not only induced apoptosis in LAM cells but also impaired key metabolic processes such as mitochondrial function and macromolecular biosynthesis, which are essential for tumor cell viability. Notably, combinatorial treatment with rapamycin, an established mTORC1 inhibitor, potentiated autophagy—a cellular clearance mechanism—highlighting a promising therapeutic synergy. This metabolic angle opens vast potential for overcoming therapeutic resistance and curbing disease progression.

The Cancer Center’s portfolio of research presented at AACR 2025 also includes advanced studies in colorectal cancer, where co-targeting HER family receptors and mutant KRAS mutations has shown efficacy, and investigations into the role of Stat1 in tumor immunity within tuberin-deficient cells, a finding with implications for LAM pathology. These multifaceted efforts underscore the Center’s broad commitment to deciphering the complex molecular and immunological landscapes that define cancers and rare diseases.

Collectively, these studies highlight the burgeoning era of precision oncology, wherein deep molecular insights are translated into targeted, patient-centric interventions. The convergence of immunology, molecular biology, and translational medicine embodied in this research holds transformative promise: personalized treatments informed by tumor and immune profiling, minimally invasive diagnostics, and combination therapies that outmaneuver tumor resistance mechanisms.

As the AACR Annual Meeting approaches, the University of Cincinnati Cancer Center’s contributions stand poised to ignite new conversations and collaborations, catalyzing advancements that may soon reshape clinical cancer care. The synthesis of fundamental discovery and applied research presented by these emerging scientists and established investigators exemplifies the dynamic pursuit of innovative solutions to some of oncology’s most pressing challenges.

Subject of Research: Head and neck cancer, breast cancer, lymphangioleiomyomatosis, cancer immunotherapy, metabolic vulnerabilities in rare diseases.

Article Title: University of Cincinnati Cancer Center Unveils Novel Insights at AACR 2025: IL-9’s Paradoxical Role, Immune Signaling Pathways, and Emerging Therapeutic Targets

News Publication Date: Information not provided.

Web References: Information not provided.

References: Information not provided.

Image Credits: Information not provided.

Keywords: Head and neck cancer, breast cancer, tumor growth, cancer immunotherapy, inhibitory effects, animal models, peripheral blood mononuclear cells, radiation therapy, NK cell receptor signaling, cell responses, cancer research.

Among this newest cohort of Damon Runyon Fellows, five have been distinguished with the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists. This award serves to recognize those individuals who have shown exceptional promise and have already exceeded the Foundation’s high expectations to a degree that positions them for profound impacts on cancer research. To facilitate their ascent in the field and magnify their potential breakthroughs, the Foundation extends an additional investment of $100,000 to these outstanding recipients, further amplifying their opportunity to revolutionize cancer treatment and prevention.

One notable Fellow, Fangyu Liu, PhD, underscores the ambitious nature of the Fellowship, expressing how its emphasis on innovation has propelled her to investigate high-risk but potentially transformative ideas. She reflects on how this support has not only exceeded her expectations but has also equipped her to glean invaluable insights that could ultimately lead to landmark discoveries. This sentiment reflects a broader ethos of the fellowship: to prioritize bold scientific inquiry as a means of propelling the field of cancer research forward.

The work of the Fellowship recipients reflects diverse and innovative studies that span a wide array of cancer types and methodologies. Rongxin Fang, PhD, at Stanford University, is employing genomic tools to decipher the intricate interactions between enhancers and promoters in cancer at the single-cell level. He is particularly focused on understanding cell communication in the healthy brain and how such communication becomes disrupted in brain tumors. This work may uncover valuable insights into manipulating genetic pathways to improve therapeutic responses for patients suffering from brain cancer.

In a separate but equally critical area of research, Xin Gu, PhD, from Dana-Farber Cancer Institute, explores the midnolin-proteasome pathway and how it facilitates the degradation of proteins, bypassing traditional tagging mechanisms involving ubiquitination. This groundbreaking discovery holds significant implications for targeting key proteins linked to blood cancers like multiple myeloma. Dr. Gu aspires to unravel the finer details of this unique pathway to pave the way for novel therapeutic strategies that could dramatically alter treatment landscapes in hematological malignancies.

Fangyu Liu’s research occupies another vital niche in the fight against cancer, as she seeks to identify novel ligands to combat various cancers, including pancreatic and colorectal cancer. Through her innovative computational techniques, she screens vast libraries of chemical compounds, aiming to create highly specific drugs that effectively target cancerous pathways while sparing healthy tissues. Liu’s pioneering findings on calcium-sensing receptors underscore her commitment to shaping the future of cancer therapy, balancing efficacy with minimized side effects to potentially reshape standard care protocols.

Equally inventive, Akanksha Thawani, PhD, is confronting the fundamental question of how retrotransposons, often termed “selfish DNA,” propagate within the human genome. She applies cutting-edge cryo-electron microscopy to visualize the structural intricacies tied to these mobile genetic components. Thawani envisions her research leading to advances in genome editing technologies capable of addressing a myriad of genetic diseases, including various cancers, ultimately contributing to improved gene therapies.

Furthermore, Qinheng Zheng, PhD, is delving into the complexities of targeted therapy, specifically focusing on reactivating tumor suppressor genes like TP53, which are commonly mutated in numerous cancers. This research could signal a breakthrough in cancer therapeutics by offering new ways to counteract oncogenic mutations that currently hinder treatment options.

As the Foundation also welcomed a new class of Damon Runyon Fellows in November 2024, the research diversity continued to expand. For instance, Saket Rahul Bagde, PhD, investigates the dynamics of hemidesmosomes within cancerous epithelial tissues to facilitate the development of personalized therapies. Using organoids to simulate tumor environments, Bagde’s work could become instrumental in tailoring treatments based on individual patient profiles.

Likewise, Longyue Lily Cao, MD, PhD, focuses on enlightening the role of dendritic cells in hepatocellular carcinoma (HCC) to enhance anti-tumor immunity through immunotherapeutic approaches. Her studies aim to uncover methods to leverage hyperactivated dendritic responses, thus potentially reshaping strategies for cancers resistant to traditional immunotherapy.

Teng Gao, PhD, seeks to deep-dive into hematopoietic stem cells (HSCs), elucidating the molecular signals that govern HSC regeneration. By navigating the uncharted territories of age-related declines and regenerative capabilities of HSCs, his research aspires to enhance stem cell therapies, opening avenues for cancer treatment breakthroughs.

Rodrigo Gier, PhD, is employing a fundamentally varied strategy focused on addressing drug resistance in tumor cells. By creatively repurposing existing therapies through drug payload strategies, Gier aims to develop innovative methods that could selectively eliminate drug-resistant cancer populations, thus greatly improving clinical outcomes.

Through their collective efforts, this cohort of scientists exemplifies the cutting-edge frontline of cancer research. Their multi-faceted approaches—from cellular communication studies to novel therapeutic methods—demonstrate the expansive potential of innovative research to unveil new horizons in cancer treatment and prevention.

The contributions of the Damon Runyon Cancer Research Foundation, alongside the unwavering dedication of these exceptional researchers, symbolize a shared commitment to fighting cancer. With each breakthrough and each novel insight, they are transforming our understanding of cancer and paving the way for future advancements that promise to change the lives of countless patients.

Together, this dynamic landscape of research underscores a hopeful trajectory toward eradicating cancer and ensuring that new and effective therapies are continuously developed. As these Fellows embark on their respective paths, the cancer research community watches closely, eagerly anticipating the innovations that will surely emerge from their groundbreaking endeavors.

—

Subject of Research: Advanced Cancer Research Techniques and Innovations
Article Title: Pioneering Research in Cancer: Damon Runyon Fellows Push the Boundaries of Science
News Publication Date: October 2023
Web References: http://damonrunyon.org
References: Not Applicable
Image Credits: Not Applicable

Keywords
Damon Runyon Cancer Research Foundation, cancer research, postdoctoral scientists, therapeutic innovations, stem cell therapy, cancer immunotherapy, gene therapy, tumor suppressor genes, drug resistance, molecular signaling, personalized medicine, breakthrough scientists